LedgmentsWe would like to acknowledge the helpful 1485-00-3 web comments on this 1379592 paper received from reviewers. We thank all our colleagues working in the Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University.Author ContributionsFinancial support: XZ. Final approval of manuscript: XZ. Conceived and designed the 
experiments: XZ. Performed the experiments: YG JY. Analyzed the data: DW SN. Contributed reagents/materials/analysis tools: DW SN. Wrote the paper: XZ YG.
Ovarian cancer 
is the most lethal gynecological malignancy. The incidence of ovarian cancer is the third in gynecologic cancer after breast and cervix cancer among women, but is the most death tolls in gynecologic cancer. The conventional course of therapy for ovarian cancer includes surgical 23977191 debulking of the tumor mass followed by adjuvant chemotherapy. Although much progress has been achieved in the development of cancer therapies in recent years, problems continue to arise particularly with respect to chemotherapy due to side-effects, resistance to and low specificity of currently available drugs [1]. Therefore, there is a need to develop safe and effective anti-cancer agents [2]. Peptide therapeutics is a promising field for emerging anticancer agents, mainly due to that these peptides can easily obtain either from nature resources or rational design based on the target protein structure. Indeed, several studies have shown that a number of bioactive peptides inhibited tumor cell growth in preclinical trails [3?]. In particular, these therapeutic peptides usually have no or limited toxicity [2]. For example, an anticancer bioactive peptide (ACBP) extracted from goat spleens dramatically inhibited human gastric tumor growth in a xenograft model with no apparent cytotoxicity to host [3]. Subsequent studies suggested that the anticancer effects of some bioactive peptides could be attributed to their abilities in induction of cell apoptosis and cell cycle arrest [3,6?]. Recent studies have revealed some peptides can impair a specific signaling pathway and subsequently inhibited the tumor growth or metastasis. Such as, a peptide of SAH-BCL(stabilized alpha helix of B cell lymphoma 9) targeting beta-catenin inhibited oncogenic Wnt activity, suppressed the growth and metastasis of colorectal cancer and multiple myeloma xenograft, and promoted the tumor cells apoptosis [8]. The hydrocarbonstapled peptide SAHM1 prevented assembly of the active transcriptional complex of Notch, and consequently inhibited cell proliferation in vitro and tumorigenesis in a mouse model of NOTCH1-driven T-cell acute leukemia and lymphoma [9]. In addition to their primary nutritional values, milk proteins are important sources of Tetracosactide biological activity biologically active peptides [10?1]. Milk proteins are the precursors of many biologically active peptides which are inactive in the precursor proteins, but can be released and activated by enzymatic proteolysis [12]. Some peptides derived from milk protein are good candidates for clinical anticancer agents or adjuvant since they are easily absorbed with less potential toxicity. Additionally, here are increasing studies showing that bioactive milk peptides can be absorbed intact from the intestinal lumen into the blood circulation – these may thus serve as novel pharmaceutical agents, which did not cause significant side effects in healthy human [13]. In fact, the exploration of the anti-cancer effects of bioactive peptides from milk proteins emerges as one of t.LedgmentsWe would like to acknowledge the helpful comments on this 1379592 paper received from reviewers. We thank all our colleagues working in the Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University.Author ContributionsFinancial support: XZ. Final approval of manuscript: XZ. Conceived and designed the experiments: XZ. Performed the experiments: YG JY. Analyzed the data: DW SN. Contributed reagents/materials/analysis tools: DW SN. Wrote the paper: XZ YG.
Ovarian cancer is the most lethal gynecological malignancy. The incidence of ovarian cancer is the third in gynecologic cancer after breast and cervix cancer among women, but is the most death tolls in gynecologic cancer. The conventional course of therapy for ovarian cancer includes surgical 23977191 debulking of the tumor mass followed by adjuvant chemotherapy. Although much progress has been achieved in the development of cancer therapies in recent years, problems continue to arise particularly with respect to chemotherapy due to side-effects, resistance to and low specificity of currently available drugs [1]. Therefore, there is a need to develop safe and effective anti-cancer agents [2]. Peptide therapeutics is a promising field for emerging anticancer agents, mainly due to that these peptides can easily obtain either from nature resources or rational design based on the target protein structure. Indeed, several studies have shown that a number of bioactive peptides inhibited tumor cell growth in preclinical trails [3?]. In particular, these therapeutic peptides usually have no or limited toxicity [2]. For example, an anticancer bioactive peptide (ACBP) extracted from goat spleens dramatically inhibited human gastric tumor growth in a xenograft model with no apparent cytotoxicity to host [3]. Subsequent studies suggested that the anticancer effects of some bioactive peptides could be attributed to their abilities in induction of cell apoptosis and cell cycle arrest [3,6?]. Recent studies have revealed some peptides can impair a specific signaling pathway and subsequently inhibited the tumor growth or metastasis. Such as, a peptide of SAH-BCL(stabilized alpha helix of B cell lymphoma 9) targeting beta-catenin inhibited oncogenic Wnt activity, suppressed the growth and metastasis of colorectal cancer and multiple myeloma xenograft, and promoted the tumor cells apoptosis [8]. The hydrocarbonstapled peptide SAHM1 prevented assembly of the active transcriptional complex of Notch, and consequently inhibited cell proliferation in vitro and tumorigenesis in a mouse model of NOTCH1-driven T-cell acute leukemia and lymphoma [9]. In addition to their primary nutritional values, milk proteins are important sources of biologically active peptides [10?1]. Milk proteins are the precursors of many biologically active peptides which are inactive in the precursor proteins, but can be released and activated by enzymatic proteolysis [12]. Some peptides derived from milk protein are good candidates for clinical anticancer agents or adjuvant since they are easily absorbed with less potential toxicity. Additionally, here are increasing studies showing that bioactive milk peptides can be absorbed intact from the intestinal lumen into the blood circulation – these may thus serve as novel pharmaceutical agents, which did not cause significant side effects in healthy human [13]. In fact, the exploration of the anti-cancer effects of bioactive peptides from milk proteins emerges as one of t.